ESMO 2016

Area: Oncology

Location: Copenhagen, Denmark

Date: October 7 to October 11

Description:

European Society for Medical Oncology Conference.


Search in Scientific Content:
Date
Filters:
Vision of
5:31

Vision of the ESMO

Presenter: Fortunato Ciardiello
Oncology
13890_PR <
5:20

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

Presenter: Lidija Kandolf-Sekulovic
Oncology
ESMO 2016:
5:42

ESMO 2016: Scientific Programme Highlights

Presenter: Andres Cervantes
Oncology
Anti-cance
5:30

Anti-cancer medicines

Presenter: Joseph Tabernero
Oncology

Full-dose neoadjuvant chemotherapy: Interi

Presenter: Alessandro Gronchi
Oncology

EORTC 18071

Presenter: Alexander M.M. Eggermont
Oncology
First-line...
9:49

First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Presenter: Gabriel N. Hortobagyi
Oncology

Primary analyss from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC.

Presenter: Fabrice Barlesi
Oncology
ASCEND-5 s
9:40

ASCEND-5 study

Presenter: Giorgio Scagliotti
Oncology

AFFINITY phase 3 trial. Chemotherapy of Prostate Cancer

Presenter: Karim Fizazi
Oncology

Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Presenter: Alain Ravaud
Oncology

Results from ALLIANCE A031203 trial

Presenter: Toni Choueiri
Oncology
Eribulin i
4:48

Eribulin in Soft Tissue Sarcomas (Leiomyosarcoma)

Presenter: Jean-Yves Blay
Oncology
ESMO 2016:
6:12

ESMO 2016: Congress Highlights

Presenter: Andres Cervantes
Oncology
13890_PR <
5:08

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

Presenter: Lidija Kandolf-Sekulovic
Oncology
MONALEESA-
8:02

MONALEESA-2 study and Novelties in breast cancer therapy

Presenter: Gabriel N. Hortobagyi
Oncology
Full-dose
7:19

Full-dose neoadjuvant chemotherapy

Presenter: Alessandro Gronchi
Oncology
EORTC 1807
15:40

EORTC 18071

Presenter: Alexander M.M. Eggermont
Oncology
Vision of
3:13

Vision of the ESMO

Presenter: Fortunato Ciardiello
Oncology
New result
4:30

New results in immun check point inhibition Lung Cancer

Presenter: Federico Cappuzzo
Oncology
The progno
5:50

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: An international multicentre hospital-based retrospective cohort study

Presenter: Matteo Lambertini
Oncology
Highlights
3:34

Highlights of Late Breaking Trials

Presenter: Stefan Zimmermann
Oncology
Checkpoint
16:60

Checkpoint inhibitors for the treatment of orphan malignancies

Presenter: Paolo A. Ascierto
Oncology
New therap
4:02

New therapeutical option: A mechanism of action study. An oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma.

Presenter: Ignacio Duran
Oncology
Highlights
6:08

Highlights of Late Breaking Trials

Presenter: Evandro de Azambuja
Oncology

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria

SABCS 2018

2018-12-04 - 2018-12-08
San Antonio, United States

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States

ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria

SABCS 2017

2017-12-05 - 2017-12-09
San Antonio, United States